GSK Shareholders

As a shareholder you will now hold a reduced number of GSK shares than your holding prior to the GSK Share Consolidation record time, but each GSK share will be worth approximately what it was worth prior to the Demerger. Your shareholding as a proportion of the total number of issued new GSK shares will be the same as before and immediately after the GSK Share Consolidation.

You will also own shares in Haleon plc, so when you add together the value of your consolidated shares in GSK and the Haleon shares you have received, the total should be approximately the same as it was in GSK shares before demerger. Normal stock market movements since 19 July 2022 may have caused subsequent changes to the value of your GSK and Haleon holdings.

Following the Demerger, the price of a GSK share fell to reflect the demerger of the Consumer Healthcare business from the GSK group. The purpose of the GSK Share Consolidation was to maintain general comparability between GSK’s share price before and after the Demerger (subject to interim market movements). The GSK Share Consolidation and the resulting consistency in share price should enable comparability between the GSK group’s earnings per share and share price with previous financial periods. It is also designed to preserve (as far as reasonably possible) the value of options and awards granted under certain GSK employee share schemes, to avoid the need for any specific adjustments to the numbers and/or exercise price of options and awards under those schemes.

A share consolidation is often carried out when companies demerge and is usually seen as beneficial by both shareholders and employees.

After the GSK Share Consolidation you now hold a reduced number of GSK shares, but each GSK share will be worth approximately what it was worth immediately prior to the Demerger and your shareholding as a proportion of the total number of issued new GSK shares remains the same as it was before the GSK Share Consolidation. Normal stock market movements since 19 July 2022 may have caused subsequent changes to the value of your GSK and Haleon holdings.

Certificates for new GSK shares were dispatched on 1 August 2022. They were sent by first class post to your registered address on the GSK share register. Share certificates are posted at the risk of shareholders.

Your existing GSK share certificate which was issued before the GSK Share Consolidation is no longer valid. Therefore, you should destroy your old share certificate upon receipt of your new GSK share certificate.

Certificates for new GSK shares were dispatched on 1 August 2022. They were sent by first class post to your registered address on the GSK share register. Share certificates will be posted at the risk of shareholders.

Dealings in new GSK shares commenced on the London Stock Exchange at 8.00am on Tuesday 19 July 2022.

Sale from GSK Nominee Service: If your New GSK Shares are held in the GSK Nominee Service, you will be able to trade your New GSK Shares through Equiniti Financial Services via its Shareview Dealing service from 8.00am on Tuesday 19 July 2022 when dealings in New GSK Shares commence on the London Stock Exchange. Your sale proceeds will be issued to you within two business days of the trade date. For more information on dealing through Shareview Dealing, including information on fees, please go to www.shareview.co.uk/Dealing or call +44 (0)3456 037 037

Sale of GSK certificated shares: If your New GSK Shares are held in certificated form, Equiniti posted your new GSK share certificate on 1 August 2022. If you wish to sell your GSK Shares, you can do this through Equiniti Financial Services via its Shareview Dealing service either online via www.shareview.co.uk/Dealing or by telephone on +44 (0)3456 037 037. If you are registered for Shareview, you can sell your New GSK Shares via www.shareview.co.uk/login. Following the sale, Equiniti Financial Services will send you a contract note and transfer form. You will need to complete and return your transfer form, together with your share certificate once received, to Equiniti Financial Services. Following receipt of your completed transfer form and share certificate, Equiniti Financial Services will issue your sale proceeds to you.

For more information on dealing through Shareview Dealing, including information on fees, please go to www.shareview.co.uk/Dealing or call +44 (0)3456 037 037

The purpose of the GSK Share Consolidation was to return the share price to its pre-Demerger level. Share Consolidation works by reducing the total number of shares in issue, so that each shareholder has fewer shares, but each share will be worth more. You will continue to own the same proportion of GSK shares as you did immediately prior to the Demerger. Of course, there can be no guarantee of post-demerger value as the actual value will depend on the market price of GSK shares.

The number of GSK shares you received as a result of the GSK Share Consolidation was determined on the evening of Monday 18 July 2022. You can view your entitlement via your Shareview Portfolio at www.shareview.co.uk/login. GSK plc Nominee Service statements and new share certificates were posted to you on 1 August 2022.

Fractional entitlements may have arisen as a result of the GSK Share Consolidation as GSK cannot issue fractional shares. Therefore, any fractional shares that you were entitled to on consolidation were sold. Individual fractional entitlements to the new GSK shares were aggregated and the resulting new GSK shares sold in the open market, on 19 July 2022 at £17.32 per share, and the net proceeds have been paid to each relevant shareholder according to his or her entitlement. These payments were made on 1 August 2022 to shareholders with bank mandates in place. Fractional entitlement payments for shareholders who do not have bank mandates in place have been retained and will be paid once bank mandate details have been received.

You can provide your bank account details:

• On Shareview at www.shareview.co.uk/info/directdividends; or
• By downloading and completing a Bank Mandate Form. This form can be found at www.shareview.co.uk/info/directdividends; or
• By contacting us to request a paper Bank Mandate Form which we can send to you. Our contact details can be found below; or
• If you hold less than 2,500 shares then we can take you bank mandate instruction over the phone. Please call us on +44 800 917 0937 and we can assist you

You will now need to provide two bank mandate instructions: one for your GSK plc shares and one for your Haleon plc shares.

If you do not have a valid dividend mandate in place, the net proceeds will be retained, and you may be charged a small fee by Equiniti for the release of the dividends.

Yes, all bank mandate and other instructions, including communication preferences given in relation to your existing GSK shares which were in force at the record time (8pm on Monday 18 July 2022) shall, unless and until revoked, be deemed to be valid and effective mandates or instructions in relation to the new GSK shares.

Please note that following the Demerger and GSK Share Consolidation, any bank mandate and/or DRIP elections that were present on your existing GSK shareholding at the Demerger and GSK Share Consolidation record dates have been copied across to your new GSK holding.

If you are registered on Shareview, personal detail changes can be made through the website at www.shareview.co.uk/login.

Alternatively, please send a covering letter giving us details of your Shareholder Reference, full registered name, your previous address and your new address. Your instruction will need to be signed.

If you have moved address and subsequently not received the documentation in relation to the Demerger, your request for duplicate documentation should be included in the address change request letter.

You can manage your shareholding online using Shareview. Set up your online portfolio at: www.shareview.co.uk/register. Once you have received your activation code in the post you can log in to unlock additional features to help you manage your GSK and Haleon shares.

You will be able to retrieve this by answering the security questions you set at registration. Please follow the Shareview forgotten login link and follow the instructions provided.

Once you have logged in to your Shareview Portfolio, you can select ‘add an investment’ from the quick links menu. You will need the Shareholder Reference Number for any holdings you’d like to add.

Yes, if you held your GSK shares through the GSK Nominee Service as at 6.00pm (UK time) on Friday 15 July 2022, your Haleon shares are held on your behalf in the new Haleon Nominee Service. This is provided by Equiniti Financial Services Limited under the Haleon Nominee Service terms and conditions which can be found at: www.shareview.co.uk/info/CSN

A Haleon Nominee Service statement will be issued to you to confirm your holding of Haleon shares held in the Haleon Nominee Service in early August 2022.

Please note that all bank mandates, DRIP elections and other instructions, including communication preferences given to Equiniti by shareholders in the GSK Nominee Service and in force at the record time (6pm (UK time) on Friday 15 July 2022) have been carried across to the Haleon Nominee Service.

Please note that following the Demerger, any bank mandate and/or DRIP elections that were present on your existing GSK shareholding at the Demerger record date have been copied across to your new holdings.

The latest share dealing terms and conditions can be found at:
https://www.shareview.co.uk/4/Info/Portfolio/Default/en/Home/Products/svd/Documents/TsCsCertificated.pdf

If you do not have a valid dividend mandate in place, any future cash distributions due to you will be retained and you may be charged a small fee by Equiniti for the release of the dividends.

You can submit your bank account details online, via Shareview portfolio. Please visit www.shareview.co.uk/info/directdividends for further details.

A bank mandate form can be downloaded if you do not wish to complete your details online. Mandate forms should be completed and returned to Equiniti as soon as possible.

We expect to process your bank mandate within 5 days of receipt at which point any fractional entitlement payment due to you, along with any retained dividend payments will be released to your bank account. Please be aware that it can take up to 10 days for any payment due to be processed and showing in your account.

Please note that any mandate instructions you provide following the Demerger will need to be given as two separate instructions, one for your GSK shares and one for your Haleon shares.

Alternatively, if you hold less than 2,500 shares then we can take you bank mandate instruction over the phone. Please call us on +44 800 917 0937 and we can assist you.

Please go to the investor section of the GSK website for further information Share scam alert | GSK

To offer the best service to all we have set up a dedicated team who you can contact via the contact us form below. By using this form, we can offer service to more customers. Alternatively, you can call us on +44 800 917 0937.

A CSN is somewhere your shares can be held electronically without the need for a share certificate. Equiniti Financial Services Limited provides a CSN for GSK and Haleon (known as the GSK plc Nominee Service and the Haleon plc Nominee Service respectively). There are no fees to hold shares in a CSN, but there are fees to deal (to buy or sell shares) and to 'transfer-out' to another broker. You must be aged 18 or over and resident in the UK, EEA, Isle of Man, Channel Islands, Switzerland or Gibraltar to participate.

Key benefits include:

• easier and more secure than holding paper share certificates – you do not need to worry about losing or misplacing your share certificate which can be expensive to replace;
• more privacy, as your name is taken off the public register and instead is kept on a separate register;
• access to competitive Equiniti dealing rates and faster settlement compared to selling shares held in certificated form;
• quarterly statements to show your share balance (if you register for Shareview you can view/download these statements online);
• no custody fees.

You must be aged 18 or over and resident in the UK, EEA, Isle of Man, Channel Islands, Switzerland or Gibraltar to participate.

Individual shareholders in the UK or EEA: Both GSK and Haleon offer a CSN. Please note that you have missed the deadline to transfer your GSK shares into the CSN before the Demerger. You will now need to complete two forms: one to transfer your GSK shares to the GSK plc Nominee Service and the other to transfer your Haleon shares to the Haleon plc Nominee Service. We can arrange to send you these forms. Please use the contact box below providing your details and request a CSN transfer form for both GSK plc and Haleon plc.

Once received, these forms should be completed and returned to Equiniti at the address shown on the form. Please note that you will need to wait to return these forms until you receive your new GSK and Haleon share certificates, which were posted to you in early August. These share certificates will need to be returned to us with the transfer forms.

All Corporates, All Trusts and individuals outside the UK and EEA: Unfortunately, you are not eligible to join the CSN as this product is only available to individuals living within the UK and EEA. If you wish to hold your shares electronically, please contact your broker who will be able to run though other options available to you.

Note: In the suite of documents issued to shareholders ahead of the General Meeting in June there was a deadline to submit the CSN Transfer Form before 4 July 2022. This deadline ensured that enrolment in both the GSK and Haleon Nominee Services would occur before the Demerger. The opportunity to transfer shares into the Nominee Services ahead of the Demerger has now passed.

Yes, Haleon is offering a Nominee Service to its shareholders. If your existing GSK Shares are currently held in the GSK plc Nominee Service you will be auto enrolled in the new Haleon plc Nominee Service for your new Haleon Shares. It will be provided by Equiniti Financial Services Limited under the Haleon plc Nominee Service terms and conditions which can be found at www.shareview.co.uk/info/CSN.

If you hold your GSK shares through the GSK plc Nominee Service, your Haleon shares will be held on your behalf in the new Haleon plc Nominee Service. This will be provided by Equiniti Financial Services Limited under the Haleon plc Nominee Service terms and conditions which can be found at www.shareview.co.uk/info/CSN.

A Haleon plc Nominee Service statement will be issued to you to confirm your holding of Haleon shares held in the Haleon plc Nominee Service in on 4 August 2022.

Please note that all bank mandates, DRIP elections and other instructions, including communication preferences given to Equiniti by shareholders in the GSK plc Nominee Service and in force at the record time (6pm (UK time) on Friday 15 July 2022) have been carried across to the Haleon plc Nominee Service.

Individual shareholders in the UK or EEA: Both GSK and Haleon offer a Nominee Service. Please note that you have missed the deadline to transfer your GSK shares into the Nominee Service before the Demerger. You will now need to complete two forms: one to transfer your GSK shares to the GSK plc Nominee Service and the other to transfer your Haleon shares to the Haleon plc Nominee Service. We can arrange to send you these forms. Please use the contact box below providing your details and request a CSN transfer form for both GSK plc and Haleon plc.

Once received these forms should be completed and returned to Equiniti at the address shown on the forms. Please note that you will need to wait to return these forms until you receive your new GSK and Haleon share certificates, which were posted to you in early August. These share certificates will need to be returned to us with the transfer forms.

Corporates, Trusts and individuals outside the UK and EEA: Unfortunately, you are not eligible to join the Nominee Service as this product is only available to individuals living within the UK and EEA. If you wish to hold your shares electronically, please contact your broker who will be able to run though other options available to you.

Note: In the suite of documents issued to shareholders ahead of the General Meeting in June there was a deadline to submit the CSN Transfer Form before 4 July 2022. This deadline ensured that enrolment in both the GSK plc and Haleon plc Nominee Services would occur before the Demerger. The opportunity to transfer shares into the Nominee Services ahead of the Demerger has now passed.

An opening statement for your Haleon shares was issued on the 4 August 2022. If you have registered for Shareview Portfolio you will receive an email when your statement is made available online which will explain how to access it.

Going forward, a quarterly statement will be made available in your Shareview Portfolio showing the number of shares held for you. We will email you to let you know this is available and how to access it. The dates statements will be made available will be provided on the front of each statement.

Your GSK plc shares and Haleon plc shares will be held on your behalf in the name of Equiniti Corporate Nominees Limited, on a separate register, which is not open to public inspection. You will continue to be the beneficial owner of the shares and will have full sight and control of your shares on www.shareview.co.uk

The latest CSN and share dealing terms and conditions can be found at: www.shareview.co.uk/info/CSN.

If your shares are held through our Equiniti Corporate Nominee Service (CSN), no paper share certificate will be produced, and you will be able to manage your shares online once you have registered for Shareview Portfolio.

No, however, if you were to sell your shares held within the Nominee Service and an outstanding residual balance of cash was to remain unclaimed for more than 12 months, we may charge an annual management fee.